Prometheus Biosciences Inc Quick Ratio (RXDX) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Prometheus Biosciences Inc   (NASDAQ: RXDX)

Prometheus Biosciences Inc 's Quick Ratio

RXDX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Prometheus Biosciences Inc 's Cash & cash equivalent grew by 2.58 % in the Q3 2023 sequentially, while Current Liabilities decreased, this led to improvement in Prometheus Biosciences Inc 's Quick Ratio to 36.9, above Prometheus Biosciences Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Quick Ratio than Prometheus Biosciences Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 93, from total ranking in the fourth quarter 2022 at 95.

Explain Quick Ratio?
How much Cash & cash equivalents RXDX´s has?
What are RXDX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RXDX Quick Ratio (Mar 31 2023)
Q3		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change 11.64 % 119.56 % 163.92 % 10.05 % 173.42 %
Y / Y Cash & cash equivalent Change 214.34 % 170.45 % -6.76 % -30.42 % -27.05 %
Quick Ratio MRQ 36.9 30.49 10.94 12.86 13.11
RXDX's Total Ranking # 93 # 95 # 379 # 174 # 301
Seq. Current Liabilities Change -15.24 % -4.05 % 44.4 % -4.95 % 66.71 %
Seq. Cash & cash equivalent Change 2.58 % 167.34 % 22.88 % -6.72 % -11.75 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 23
Overall Market # 93


Quick Ratio Statistics
High Average Low
94.71 17.91 0
(Aug 31 2013)   (Sep 30 2013)




Financial Statements
Prometheus Biosciences Inc 's Current Liabilities $ 19 Millions Visit RXDX's Balance sheet
Prometheus Biosciences Inc 's Cash & cash equivalent $ 714 Millions Visit RXDX's Balance sheet
Source of RXDX's Sales Visit RXDX's Sales by Geography


Cumulative Prometheus Biosciences Inc 's Quick Ratio

RXDX's Quick Ratio for the trailling 12 Months

RXDX Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 59.42 % 97.51 % 60.71 % -1.45 % -11.62 %
Y / Y Cash & cash equivalent TTM Growth 76.2 % 21.08 % 0.78 % 19.71 % 58.05 %
Quick Ratio TTM 22.83 17.35 14.07 18.33 20.66
Total Ranking TTM # 3185 # 3405 # 3351 # 3255 # 3116
Seq. Current Liabilities TTM Growth 2.51 % 18.28 % 27.76 % 2.91 % 27 %
Seq. Cash & cash equivalent TTM Growth 34.89 % 45.85 % -1.93 % -8.67 % -7.31 %

Quick ratio ranking by company, industry and sector >> Back to RXDX Financial Strength Comparisons >> Go to Compare RXDX Quick Ratio to its Competitors

On the trailing twelve months basis RXDX Cash & cash equivalent more than doubled by 214.34 % in Q3 2023 year on year, faster than Current Liabilities, this led to increase in in Prometheus Biosciences Inc 's Quick Ratio to 22.83, above RXDX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 545 other companies have achieved higher Quick Ratio than Prometheus Biosciences Inc . While Quick Ratio overall ranking has improved so far to 3185, from total ranking during the twelve months ending fourth quarter 2022 at 3405.

Explain Quick Ratio?
How much Cash & cash equivalents RXDX´s has?
What are RXDX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 546
Healthcare Sector # 1041
Within the Market # 3185


trailing twelve months Quick Ratio Statistics
High Average Low
22.83 12.74 5.56
(Mar 31 2023)   (Mar 31 2017)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Tyra Biosciences Inc   65.64 $ 241.701  Millions$ 3.682  Millions
Rafael Holdings Inc  59.63 $ 82.403  Millions$ 1.382  Millions
Xbiotech Inc   58.78 $ 212.662  Millions$ 3.618  Millions
Karuna Therapeutics Inc   58.42 $ 1,474.454  Millions$ 25.237  Millions
Third Harmonic Bio Inc   57.05 $ 282.202  Millions$ 4.947  Millions
Nuvation Bio Inc   51.52 $ 646.609  Millions$ 12.551  Millions
Greenwich Lifesciences Inc   50.56 $ 11.911  Millions$ 0.236  Millions
Atea Pharmaceuticals Inc   50.20 $ 620.488  Millions$ 12.361  Millions
Enliven Therapeutics Inc   49.85 $ 292.102  Millions$ 5.860  Millions
Structure Therapeutics Inc   48.71 $ 240.862  Millions$ 4.945  Millions
Barinthus Biotherapeutics Plc  44.22 $ 191.328  Millions$ 4.327  Millions
Merrimack Pharmaceuticals Inc  41.90 $ 19.401  Millions$ 0.463  Millions
Aprea Therapeutics Inc   37.52 $ 30.996  Millions$ 0.826  Millions
Prometheus Biosciences Inc   36.90 $ 713.670  Millions$ 19.340  Millions
Theseus Pharmaceuticals Inc   35.72 $ 236.634  Millions$ 6.624  Millions
Adc Therapeutics Sa  35.72 $ 310.547  Millions$ 8.694  Millions
Atossa Therapeutics Inc   35.32 $ 103.978  Millions$ 2.944  Millions
Design Therapeutics Inc   34.86 $ 315.392  Millions$ 9.047  Millions
Cyteir Therapeutics Inc   34.64 $ 137.204  Millions$ 3.961  Millions
Oramed Pharmaceuticals Inc  32.50 $ 153.734  Millions$ 4.730  Millions
Arca Biopharma Inc  32.27 $ 40.850  Millions$ 1.266  Millions
Dice Therapeutics Inc   32.16 $ 554.548  Millions$ 17.241  Millions
Astria Therapeutics Inc   31.97 $ 213.328  Millions$ 6.673  Millions
Altimmune inc   31.64 $ 165.729  Millions$ 5.238  Millions
Morphic Holding inc   31.25 $ 421.279  Millions$ 13.481  Millions
Ironwood Pharmaceuticals inc   31.05 $ 740.342  Millions$ 23.843  Millions
Neurogene Inc   30.87 $ 167.358  Millions$ 5.421  Millions
Nanoviricides inc   27.68 $ 9.651  Millions$ 0.349  Millions
Ars Pharmaceuticals Inc   26.89 $ 264.549  Millions$ 9.838  Millions
Acelyrin Inc   26.85 $ 289.194  Millions$ 10.770  Millions

Date modified: 2026-09-26T07:39:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.